Literature DB >> 3178269

Incidence of retinopathy of prematurity in New Zealand.

B A Darlow1.   

Abstract

The incidence of retinopathy of prematurity has been prospectively assessed in very low birthweight infants born in one year in New Zealand. A total of 26 (11%) surviving infants with birth weight 1000-1499 g had acute retinopathy. Forty one (49%) surviving infants with birth weight 500-999 g had acute retinopathy and of these six (7%) became bilaterally totally blind.

Entities:  

Mesh:

Year:  1988        PMID: 3178269      PMCID: PMC1779134          DOI: 10.1136/adc.63.9.1083

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  4 in total

1.  Outcome in infants 501 to 1000 gm birth weight delivered to residents of the McMaster Health Region.

Authors:  S Saigal; P Rosenbaum; B Stoskopf; J C Sinclair
Journal:  J Pediatr       Date:  1984-12       Impact factor: 4.406

2.  Retinopathy of prematurity: an estimate of vision loss in the United States--1979.

Authors:  D L Phelps
Journal:  Pediatrics       Date:  1981-06       Impact factor: 7.124

3.  Retinopathy of prematurity. Diagnosis, severity, and natural history.

Authors:  J T Flynn; E Bancalari; B N Bachynski; E B Buckley; R Bawol; R Goldberg; J Cassady; J Schiffman; W Feuer; D Gillings
Journal:  Ophthalmology       Date:  1987-06       Impact factor: 12.079

4.  Retinopathy of prematurity: review of a five-year period, examination techniques and recommendations for screening.

Authors:  R S Clemett; B A Darlow; R R Hidajat; K H Tarr
Journal:  Aust N Z J Ophthalmol       Date:  1986-05
  4 in total
  16 in total

1.  Regionalisation of retinopathy of prematurity (ROP) screening improves compliance with guidelines: an audit of ROP screening in the Northern Region of England.

Authors:  N G Ziakas; D G Cottrell; D W Milligan; P M Pennefather; M A Bamashmus; M P Clarke
Journal:  Br J Ophthalmol       Date:  2001-07       Impact factor: 4.638

2.  Outcomes for high risk New Zealand newborn infants in 1998-1999: a population based, national study.

Authors:  A E Cust; B A Darlow; D A Donoghue
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-01       Impact factor: 5.747

3.  Improved outcomes for very low birthweight infants: evidence from New Zealand national population based data.

Authors:  B A Darlow; A E Cust; D A Donoghue
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-01       Impact factor: 5.747

4.  Initial experience of screening for retinopathy of prematurity.

Authors:  D I Clark; C O O'Brien; A M Weindling; M Saeed
Journal:  Arch Dis Child       Date:  1992-10       Impact factor: 3.791

Review 5.  Screening for retinopathy of prematurity.

Authors:  A R Fielder; M I Levene
Journal:  Arch Dis Child       Date:  1992-07       Impact factor: 3.791

Review 6.  Genetic susceptibility to retinopathy of prematurity: the evidence from clinical and experimental animal studies.

Authors:  Gerd Holmström; Peter van Wijngaarden; Douglas J Coster; Keryn A Williams
Journal:  Br J Ophthalmol       Date:  2007-12       Impact factor: 4.638

7.  Ophthalmological long-term follow up of preterm infants: a population based, prospective study of the refraction and its development.

Authors:  M Holmström; M el Azazi; U Kugelberg
Journal:  Br J Ophthalmol       Date:  1998-11       Impact factor: 4.638

8.  Three year visual outcome for treated stage 3 retinopathy of prematurity: cryotherapy versus laser.

Authors:  I A Pearce; F C Pennie; L M Gannon; A M Weindling; D I Clark
Journal:  Br J Ophthalmol       Date:  1998-11       Impact factor: 4.638

9.  Ophthalmological follow up of preterm infants: a population based, prospective study of visual acuity and strabismus.

Authors:  G Holmström; M el Azazi; U Kugelberg
Journal:  Br J Ophthalmol       Date:  1999-02       Impact factor: 4.638

10.  Screening for retinopathy of prematurity: evaluation and modification of guidelines.

Authors:  E Larsson; G Holmström
Journal:  Br J Ophthalmol       Date:  2002-12       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.